Chennai Home>
Chennai Health Home >
A Personal Word: The X-ray
Deserves Its Honored Place in Health
The finding, that radiation from medical procedures is a
major cause of both Cancer and Ischemic Heart Disease, does
not argue against the use of x-rays, CT scans, fluoroscopy,
and radioisotopes in diagnostic and interventional
radiology. Such uses also make very positive contributions
to health. We deeply respect those contributions, and the
men and women who achieve them.
This author is most definitely not "anti-x-ray" or
"radio-phobic." As a graduate student in physical chemistry,
I worked very intimately with radiation, in the quest for
the first three atomic-bombs. Subsequently, in medical
school, I considered becoming a radiologist. In the late
1940s, I did nuclear medicine with patients having a variety
of hematological disorders. In the 1960s, I did chemical
elemental analysis of human blood by x-ray spectroscopy. In
the early 1970s, our group at the Livermore National
Laboratory induced genomic instability in human cells with
gamma rays.
In short, I fully appreciate the benefits and insights (in
medicine and other fields) which ionizing radiation makes
possible.
But no one honors the x-ray by treating it casually or by
failing to acknowledge that it is a uniquely potent mutagen.
One honors the x-ray by taking it seriously.
While doses from diagnostic and interventional radiology are
very low relative to doses used for cancer therapy,
diagnostic and interventional x-ray doses today are far from
negligible. The widely used CT scans, and the common
diagnostic examinations which use fluoroscopy, and
interventional fluoroscopy (e.g., during surgery), deliver
some of the largest nontherapeutic doses of x-rays. In 1993,
the United Nations Scientific Committee on the Effects of
Atomic Radiation warned, appropriately, in its Annual
Report:
"Although the doses from diagnostic x-ray examinations are
generally relatively low, the magnitude of the practice
makes for a significant radiological impact."
In the USA until about 1970, fetal irradiation occurred
during ~ 1 pregnancy per 14.
Every Benefit of Medical Radiation: Same Procedures,
Lower Dose-Levels
The fact that ionizing radiation is a uniquely potent
mutagen, and the finding that radiation from medical
procedures is a major cause of both Cancer and Ischemic
Heart Disease, clearly indicate that it would be appropriate
in medicine to treat dosage of ionizing radiation at least
as carefully as we treat dosage from potent medications. In
the medical professions, we do not administer unmeasured
doses of powerful pharmaceuticals, and we do not take a
casual view of a 5-fold, 10-fold, even 20-fold elevation in
dosage of such medications.
By contrast, in both the past and the present, unmeasured
doses of x-rays are the rule -- - not the exception. When
sampling has been done, in which actual measurements are
taken, dosage has been found to vary from one facility to
another by many-fold, for the same procedure for patients of
the same size.
The reason for large variation is obvious from the list of
numerous proven ways to reduce dosage. Facilities which
apply all the measures can readily achieve average doses
more than 5-fold lower than facilities which apply very few
measures.
Certain Spinal X-rays: A Dramatic Demonstration
The potential for dose-reduction may far exceed 5-fold for
some common x-ray exams. This has already been demonstrated
for the spinal x-rays employed to monitor progress in
treating idiopathic adolescent scoliosis, a lateral
curvature of the spine. An estimated 5% of American
children, or more, have this disorder. In a most responsible
way, Dr. Joel Gray and coworkers at the Mayo Clinic
developed radiologic techniques for scoliosis monitoring
which can reduce measured x-ray dose to various organs as
follows:
Abdominal exposure: 8-fold reduction.
Thyroid exposure: 20-fold reduction (with a back to front
radiograph), and 100-fold reduction (with a lateral
radiograph).
Breasts: 69-fold reduction (with a back to front
radiograph), and 55-fold reduction (with a lateral
radiograph).
They report, "These reductions in exposure were obtained
without significant loss in the quality of the radiographs
and in most instances, with an improvement in the over-all
quality of the radiograph due to the more uniform exposure.
Mammography: A Model of Success
The importance of dose-reduction for the mammographic
examination has been recognized, and such doses have been
reduced by about a factor of ten in recent years. "Where
there is a will, there is a way." In certified mammography
centers today, doses are routinely verified periodically,
and measurements provide the feedback required, in order to
achieve constant dose-reduction instead of upward creep.
The Benefits of Every Procedure -- - with Far Less Dose
Dose-reduction can be a truly safe measure. It is clear that
average per patient doses from diagnostic and interventional
radiology could be reduced by a great deal without reducing
the medical benefits of the procedures in any way.
Radiography: Quality-assurance (dose-reduction by an average
factor of 2), beam-collimation (by a factor up to 3),
rare-earth screens (by a factor of 2 to 4), rare-earth
filtration (by a factor of 2 to 4), use of carbon-fibre
materials (by a factor of 2), gonadal shielding (by a factor
of 2 to 10 for the gonads).
Digital Radiography: Decrease in contrast resolution, when
such resolution is not needed (dose-reduction by a factor of
2 to 3), use of a pulsed system (by a factor of 2).
Fluoroscopy: Changes in the operator's technique
(dose-reduction by a factor of 2 to 10), variable aperture
iris on TV camera (by a factor of 3), high and low
dose-switching (by a factor of 1.5), acoustic signal related
to dose-rate (by a factor of 1.3), use of a 105mm camera (by
a factor of 4 to 5). Additional methods not specified in the
list: Use of a circular beam-collimator when the
image-receiver is circular, adoption of "freeze-frame" or
"last-image-hold capability, and restraint in recording
fluoroscopic images.
An Immense Opportunity: All Benefit, No Risk
The evidence in this monograph, on an age-adjusted basis, is
that most fatal cases of Cancer and Ischemic Heart Disease
would not happen as they do, in the absence of x-ray-induced
mutations. We look forward to responses to our findings.
We have also presented findings, from outside sources, that
average per patient radiation doses from diagnostic and
interventional radiology could be reduced by a great deal,
without reducing the medical benefits of the procedures in
any way. The same procedures can be done at substantially
lower dose-levels.
Does the Public Need a Denial, "For Its Own Good" ?
One type of response to this monograph may be that the
findings need to be denied immediately (without
examination), lest the public refuse to accept the benefits
of x-ray procedures.
This type of response, insulting to the public, would not be
consistent with reality. In reality, the public accepts a
host of dangerous medications and procedures, in exchange
for their demonstrable benefits -- - sometimes, for
undemonstrated benefits. Very few people will forego the
obvious benefits from diagnostic and interventional
radiology, just because such procedures confer a risk of
subsequent Cancer and IHD.
The only change will probably be that people will demand
that the same degree of care, now exercised with respect to
dosage of potent medications, be exercised with respect to
dosage of radiation from each procedure. They will want to
avoid a dose-level of, say, ten rads -- - if the same
information could be acquired with one rad. They do not
deserve "one useful part of information, and nine
unnecessary parts of extra risk of Cancer and IHD." Patients
will want more measurements, and fewer assumptions, about
the doses delivered. But they will not reject the procedures
themselves.
The "Advocacy Issue" and the Hippocratic Oath
It is very often said that, if scientists advocate any
action based on their findings, they undermine their
scientific credibility. If such scientists stand to benefit
financially from the actions they advocate, such suspicion
occurs naturally. But even in such circumstances, if their
work is presented in a way which anyone can replicate, it
should be impossible for their advocacy to diminish the
scientific credibility of their work.
Our findings are not encumbered either by financial
interests or by any barriers to replication. The findings
stand on their own, whether or not we advocate any action.
I have spent a lifetime studying the causes of Ischemic
Heart Disease, and then Cancer, in order to help prevent
such diseases. So it would be pure hypocrisy for me to feign
a lack of interest in any preventive action which would be
both safe and benign. And when sources, completely
independent from me, set forth their findings that such
action is readily feasible -- - namely, significant
dose-reduction in diagnostic and interventional radiology --
- it would be worse than silly for me to pretend that I have
no idea what action should occur.
After all, as a physician, I took the Hippocratic Oath:
"First, do no harm." Silence would contribute to the harm of
millions of people.
Why Wait? What Is the Purpose?
Although it is commonly assumed that radiation doses are
"negligible" from modern medical procedures, the assumption
is definitely mistaken.
An estimated 35% to 50% of some higher-dose diagnostic
procedures are currently received by patients below age 45
-- - when the carcinogenic impact per dose-unit is probably
stronger than it is after age 65 or so.
In diagnostic and interventional radiology, dose-reduction
would be wholly safe, quite inexpensive, and guaranteed
beneficial -- - because induction of Cancer by ionizing
radiation has been an established fact for decades.
A Mountain of Solid Evidence That Each Dose Matters
The fact, that x-ray doses are so seldom measured, reflects
the false assumption that such doses do not matter. This
monograph has presented a mountain of solid evidence that
they do matter, enormously.
And each bit of additional dose matters, because any x-ray
photon may be the one which sets in motion the high-speed
high-energy electron which causes a carcinogenic or
atherogenic mutation. Such mutations rarely disappear. The
higher their accumulated number in a population, the higher
will be the population's mortality-rates from
radiation-induced Cancer and Ischemic Heart Disease.
The x-ray is a proven mutagen and a proven cause of Cancer,
and the evidence in this book strongly indicates that it is
also a very important cause of Cancer and a very important
atherogen. From the existing evidence, it is clear that
average per patient doses from diagnostic and interventional
radiology could be reduced by a great deal without reducing
the medical benefits of the procedures in any way.
A Prudent Position from Which No One Loses, Everyone Gains
Whether diseases are common or rare, a prime reason for
studying their causation is prevention. Cancer and Ischemic
Heart Disease, combined, accounted for 45% of all deaths in
the USA during 1993.
If we in the medical professions take the position, that we
should not press for reducing doses from medical radiation
until every question has been perfectly answered, then we
can never undo the harm inflicted during the waiting period,
upon tens of millions of patients every year.
By contrast, if we take the prudent position that
dose-reduction should become a high priority without delay
(and if humans do not start exposing themselves to some
other potent mutagen), the evidence in this monograph
indicates that we will prevent much of the future mortality
from Cancer and Ischemic Heart Disease, without causing any
adverse effects on health. No one loses, everyone gains.
Radiation from Medical Procedures in the Pathogenesis of
Cancer and Ischemic Heart Disease
http://www.ratical.org/radiation/CNR/RMP/chp1F.html
Dr. Joseph Mercola's comment:
After four years one would think I would have posted a study
regarding the relationship between X-rays and cancer. I had
not seen a scholarly work like this in the past. Now, now
only do we understand that x-rays are highly linked with
cancer, but they are also linked with heart disease.
Dr. Gofman's credentials are astounding. Not only does he
have a Ph.D in nuclear and physical chemistry, but he is
also a medical doctor:
While a graduate student at U.C. Berkeley, Gofman earned his
Ph.D. (1943) in nuclear/physical chemistry, with his
dissertation on the discovery of Pa-232, U-232, Pa-233, and
U-233, the proof that U-233 is fissionable by slow and fast
neutrons, and discovery of the 4n + 1 radioactive series.
His faculty advisor was Glenn T. Seaborg (who became
Chairman of the Atomic Energy Commission, 1961-1971).
Post-doctorally, Gofman continued research related to the
first atomic bombs -- - particularly the chemistry of
plutonium, at a time when the world's total supply was less
than 0.25 milligram. He shares patents #2,671,251 and
#2,912,302 on two processes for separating plutonium from
the uranium and fission products of irradiated nuclear fuel.
After the plutonium work, Gofman completed medical school
(1946) at UCSF. In 1947, following his internship in
Internal Medicine, Gofman joined the faculty at U.C.
Berkeley (Division of Medical Physics), where he began his
research on lipoproteins and Coronary Heart Disease at the
Donner Laboratory.
In 1954, Gofman received the Modern Medicine Award for
outstanding contributions to heart disease research. In
1965, he received the Lyman Duff Lectureship Award of the
American Heart Association, for his research in
atherosclerosis and Coronary Heart Disease. In 1972, he
shared the Stouffer Prize for outstanding contributions to
research in arteriosclerosis. In 1974, the American College
of Cardiology selected him as one of twenty-five leading
researchers in cardiology of the past quarter-century.
Meanwhile, in the early 1960s, the Atomic Energy Commission
(AEC) asked Gofman to establish a Biomedical Research
Division at the AEC's Livermore National Laboratory, for the
purpose of evaluating the health effects of all types of
nuclear activities.
From 1963-1965, Gofman served as the division's first
director and concurrently as an Associate Director of the
full laboratory. Then he stepped down from the
administrative activities in order to have more time for his
own laboratory research on Cancer and chromosomes (the
Boveri Hypothesis), on radiation-induced chromosomal
mutations and genomic instability, and for his analytical
work on the epidemiologic data from the Japanese atomic-bomb
survivors and other irradiated human populations.
By 1969, Gofman and a Livermore colleague, Dr. Arthur R.
Tamplin, had concluded that human exposure to ionizing
radiation was much more serious than previously recognized.
Because of this finding, Gofman and Tamplin spoke out
publicly against two AEC programs which they had previously
accepted. One was Project Plowshare, a program to explode
hundreds or thousands of underground nuclear bombs in the
Rocky Mountains in order to liberate (radioactive) natural
gas, and to use nuclear explosives also to excavate harbors
and canals. The second was the plan to license about 1,000
commercial nuclear power plants (USA) as quickly as
possible. In 1970, Gofman and Tamplin proposed a 5-year
moratorium on that activity.
The AEC was not pleased. Seaborg recounts some of the heated
conversations among the Commissioners in his book The Atomic
Energy Commission under Nixon: Adjusting to Troubled Times
(1993). By 1973, Livermore de-funded Gofman's laboratory
research on chromosomes and Cancer. He returned to teaching
full-time at U.C. Berkeley, until choosing an early and
active "retirement" in order to concentrate fully on
pro-bono research into human health-effects from radiation.
His 1981, 1985, 1990, 1994, and 1995/96 books present a
series of findings. His 1990 book includes his proof, "by
any reasonable standard of biomedical proof," that there is
no threshold level (no harmless dose) of ionizing radiation
with respect to radiation mutagenesis and carcinogenesis --
- a conclusion supported in 1995 by a government-funded
radiation committee. His 1995/96 book provides evidence that
medical radiation is a necessary cofactor in about 75% of
the recent and current Breast Cancer incidence (USA) -- - a
conclusion doubted but not at all refuted by several
peer-reviewers.